High alanine aminotransaminase associated with daptomycin use in a premature infant

Suzan Suhail Asfour1, Fahad Aljobair2, Adli Abdelrahim3

  • 1Clinical Pharmacy Department, Pharmacy Department, King Saud Medical City, Riyadh, Saudi Arabia.

Insights

Daptomycin, an antibiotic for gram-positive infections, may cause liver damage in premature infants. A case study revealed elevated liver enzymes and coagulation issues shortly after daptomycin administration in a neonate.

Area of Science:

  • Pharmacology
  • Neonatal Medicine
  • Infectious Diseases

Background:

  • Daptomycin is a lipopeptide antibiotic effective against gram-positive bacteria.
  • Its use in premature infants is established for various infections.

Purpose of the Study:

  • To report a case of potential hepatotoxicity in a premature infant receiving daptomycin.
  • To highlight a previously unrecognized adverse drug effect.

Main Methods:

  • Case report of a premature infant treated with daptomycin.
  • Monitoring of liver function tests (alanine aminotransaminase) and coagulation parameters (prothrombin time, international normalised ratio).

Main Results:

  • The infant developed elevated alanine aminotransaminase, prolonged prothrombin time, and increased international normalised ratio.
  • These changes occurred rapidly following daptomycin administration.

Conclusions:

  • Daptomycin may be associated with hepatotoxicity and coagulopathy in premature infants.
  • Close monitoring for liver function and coagulation is recommended in this population.

Related Concept Videos

Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
26
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
28
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
33
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
19